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Abstract - Constitutive androstane receptor (CAR) is a nuclear receptor implicated in many 
physiological activities of the cell1. Although it has the structural capability to function in the 
absence of a bound ligand, CAR has a wide variety of known ligands, such as CINPA-1, and the 
interaction with these ligands is important for possible drug treatment therapies. This study 
amplified the genetic construct for CAR by polymerase chain reaction (PCR), grafted it into a 
plasmid, and transformed Escherichia coli strains so that they acquired the plasmid. The strains 
were then assayed for CAR expression, and the strain with the best expression was grown for 
large-scale protein expression. The protein was isolated via affinity chromatography and further 
purified by size-exclusion chromatography. After purification the protein was concentrated and 
flash-frozen for long-term storage. A crystallization conditions screening was performed to 
determine the structure of CAR and its interaction with CINPA-1, but this screen was 





Nuclear receptors are common in signal 
transduction pathways. With the human 
genome encoding 48 different types of 
nuclear receptors1, they are thought to be 
among the most prevalent families of 
transcriptional regulators in the Animal 
Kingdom2. The term transcriptional 
regulator stems from the nuclear receptor’s 
ability to modulate transcription of an 
organism’s genome in various ways. They 
achieve this by directly interacting with the 
DNA at a regulatory site specific to the 
target gene. When activated by a specific 
signal, the nuclear receptor is transported 
through the nuclear pore into the nucleus, 
where it is then able to find and bind to a 
specific DNA sequence. This sequence is 
recognized by a distinct region of the 
nuclear receptor, termed the DNA-binding 
domain, or DBD2 (Figure 1). This region is 
highly conserved between receptors and 
possesses a zinc-finger motif, which allows 
site-specific interaction with the DNA 
double helix2. If this interaction increases 
transcription, the receptor is said to be an 
enhancer. If the opposite effect is achieved, 
the receptor behaves as a silencer, as the 
gene it acts on becomes expressed less 
frequently.   
     Another characteristic of nuclear 
receptors involves their activation 
mechanism. As implied by the name, a 
nuclear receptor receives some sort of 
environmental signal. This can be a peptide 
or hormone, for example, and it interacts 
with a specialized region of the receptor, 
namely the LBD, or the ligand-binding 
domain2 (Figure 1). The LBD recognizes its 
ligand, and amino acids of the receptor form 
molecular interactions with the ligand. 
These interactions trigger a conformational 
change in the receptor that either activates or 
inactivates it. When activated, the nuclear 
receptor is able to carry out its function in 
the nucleus; when inactivated, the protein is 
unable to do so. Thus, the LBD serves an 
important role in regulating the activity of 
the entire receptor.  
     Constitutive androstane receptor (CAR) 
is a member of the nuclear receptor 
superfamily. When activated, it elicits a 
cellular response by modifying transcription, 
creating a cascade of events downstream 
that modifies the behavior of the cell in 
various ways1. Unlike most nuclear 
receptors, however, CAR displays unusual 
activity in that it can become activated even 
in the absence of one of its ligands3. In this 
event, CAR is activated in response to a 
separate cellular signaling pathway. This 
usually occurs via phosphorylation or 
dephosphorylation of a threonine toward the 
N’ terminus3. This biochemical activity is 
important for the proper nuclearization of 
CAR, and the removal of the phosphoryl 
group on Thr-38 results in CAR being 
shuttled into the nucleus where it can 
properly function3.  
     CAR usually exists in a multi-protein 
complex in the cytoplasm. This complex is 
then broken down and CAR is freed to enter 
the nucleus. This breakdown is regulated by 
both protein kinases and phosphatases, such 
as protein kinase A (PKA) and protein 
phosphatase 2A (PP2A)3. PKA and PP2A 
are each activated as the result of various 
signaling pathways. When PKA is activated, 
it phosphorylates CAR, which effectively 
sequesters it in the cytoplasm. PP2A 
dephosphorylates CAR, freeing it to enter 
the nucleus. Because of the nature of these 
PKA and PP2A pathways, CAR is thus 
activated independently of binding one of its 
ligands. Furthermore, the oppositional 
nature of these signaling pathways helps to 
keep CAR activity closely regulated. 
     In addition to this indirect method of 
activation, CAR can also be stimulated 
directly through interaction with ligands. 
CAR has been shown to have a variety of 
ligands, such as CINPA-1. These ligands 
can be either agonists or antagonists. 
Because of its constitutive nature, unbound 
CAR is in an active state when inside the 
nucleus3. This activity, however, is 
modulated by ligand-binding interactions; 
agonists serve to increase the activity while 
antagonists decrease its activity. Because 
CAR is involved in so many cellular 
processes, its regulation can be the key to 
Figure 1. General Structure of the Nuclear Receptor, CAR. 
The typical nuclear receptor has two major regions of activity. The DNA-binding domain (blue) marks the site 
where the protein is able to interact directly with the DNA (black), which elicits a change in the transcription for 
a certain gene. The other conserved domain is the ligand-binding domain (green), which allows regulation of the 
nuclear receptor via interaction with various, specific ligands (red). 
understanding many other biochemical 
pathways in the cell.  
     One such pathway that is regulated by 
CAR is involved in drug efflux. The major 
mechanism through which CAR affects this 
is by transcriptional control of the gene 
multiple drug resistance 1 (MDR1)4. This 
gene encodes P-glycoprotein, which serves 
as a drug efflux pump5. This pump is 
implicated in multiple drug resistance; it is 
able to remove many different types of 
drugs from accumulating within the cell. 
This lack of accumulation means that 
medication cannot become concentrated 
enough to reach an effective dose, and this 
has become a problem for drug treatment 
therapies such as various chemotherapy 
regiments used to target cancerous cells.  
     For patients with a cancer diagnosis, the 
level of P-glycoprotein expression can be a 
strong predictor of their recovery outlook5. 
Typically, the more P-glycoprotein 
expressed, the less likely the patient will 
respond well to chemotherapy. Since this 
gene is regulated by CAR, it is possible that 
treating CAR with an antagonist can have 
the downstream effect of reducing 
expression of P-glycoprotein and thus 
increasing the susceptibility of cancer cells 
that previously were multi-drug resistant.  
 
Materials and Methods 
 
Plasmid Preparation 
Site-specific mutagenesis was performed 
using pET15b6HisMBP-hCAR-LBD vector 
as the template DNA strand. Two reaction 
mixtures were prepared: one contained 1μM 
of 5x Phusion High-Fidelity buffer, 0.4μM 
dNTPs, 0.25μM of both the forward and 
reverse primers, 0.25μL of Phusion DNA 
polymerase, and 5ng of template DNA 
(PCR5), and the other contained the same 
concentrations of solutions with 10ng of 
template DNA (PCR10). The final reaction 
volumes were brought to 50μL by adding 
autoclaved deionized water. The reaction 
vessels were vortexed prior to the addition 
of Phusion, and were gently mixed before 
placement in the thermocycler. The initial 
denaturation temperature was programmed 
to 95°C for 3 minutes. The replication cycle 
was set to repeat 20 times with the following 
program: 95°C denaturation for 30 seconds, 
55°C annealing for 30 seconds, and 72°C 
extension for 10 minutes. There was one 
final extension period of 10 minutes at 72°C 
after which the reaction was held at 4°C. 
The sample was then run on a 2.5% agarose 
gel to ensure proper amplification.  
     The PCR product was treated with 1μL 
of the restriction enzyme Dpn1 in 5 μL of 
CutSmart buffer. The reaction mixture was 
incubated at 37°C for one hour and was 
shaken at 225rpm for the first 30 minutes. 
This reaction was used to transform DH5α 
E. coli cells by heat shock. 2μL of the Dpn1 
digestion reaction product was added to an 
eppendorf tube containing DH5α cells. The 
mixture was flicked gently to mix and set on 
ice for 20 minutes. The tube was heat 
shocked for 45 seconds in a 42°C water 
bath, and the mixture was then set in ice for 
5 minutes. 450μL of 2XYT medium was 
added to the cells to bring the total volume 
up to 500μL, and the tube was placed in the 
37°C shaker for 1 hour at 225rpm. This was 
repeated twice, once for PCR5 and once for 
PCR10. After incubation the samples were 
streaked on agar plates containing 
kanamycin and stored at 37°C overnight. 
Glycerol stocks were prepared for 5 
transformant colonies from PCR5 and 2 
transformant colonies from PCR10. These 
were stored at -80°C.  
     The plasmids from these stocks were 
isolated using Zymo Research Plasmid 
Miniprep-Classic kit, and concentrations 
were determined using a Nanodrop 
instrument. Three samples were submitted 
for sequencing using the Sanger sequencing 
method. Results were analyzed using 
ExPASy Translate Tool6 and NCBI Align 
Sequence Nucleotide BLAST7.  
 
Expression Screening 
The plasmids pET15b6HisMBP-hCAR 
PCR5-5 and pET15b6HisMBP-hCAR 
PCR10-1 were used to transform two strains 
of E. coli used for protein expression, RIPL 
and BL21. These transformation reactions 
followed the same protocol for the DH5α 
heat-shock transformation above, with the 
only exception being 4μL of plasmid added 
to the 100μL BL21 glycerol stocks to ensure 
that the cell to plasmid ratio was constant. 
The final volumes for the reaction were 
brought to 500μL by the addition of 400μL 
of 2XYT media to BL21 cells and 450μL of 
2XYT media to RIPL cells. These reactions 
were placed in the 37° shaker at 225rpm for 
1 hour. After incubation, the reaction tubes 
were centrifuged at 4000rpm for 1 minute to 
concentrate the cells toward the bottom of 
the tube, without forming a pellet. The top 
400μL were disposed of, and the remaining 
100μL were spread on agar plates. The 
plates for RIPL cells contained two 
antibiotics, kanamycin and chloramphenicol, 
while the plates for BL21 cells contained 
only kanamycin. Both plates were kept at 
37°C overnight for growth. 
     5 colonies from each of the 4 plates, were 
transferred to 5 test tubes containing 5mL of 
2XYT liquid medium and the appropriate 
antibiotics. These cultures were grown 
overnight in the 37°C shaker set at 225rpm. 
The next day, 30% glycerol stocks were 
made from the overnight cultures by mixing 
700μL of the culture with 300μL of 
glycerol. The glycerol stocks were then kept 
at -80°C. An additional 50μL from each 
culture was used to inoculate another 5mL 
of 2XYT liquid medium with appropriate 
antibiotics. These cultures were grown in the 
37°C shaker at 225rpm to an optical density 
(OD) of 0.7 at which point they were each 
induced with 2.5μL of IPTG and kept in a 
20°C shaker at 225rpm for 20 hours.  
     The cultures were removed from the 
shaker after 20 hours, and 1mL of each 
sample was centrifuged for 5 minutes at 
13000rpm. A sample of each pellet was 
taken and a Western blot was performed to 
verify correct protein expression.  
 
Small-Scale Protein Preparation 
Using the glycerol stocks prepared for each 
of the selected strains, a small-scale protein 
preparation was performed to more 
accurately screen for highest MBP-hCAR 
expression and isolation. A small sample 
from each glycerol stock was taken using a 
sterile inoculation loop, which was also used 
to streak agar plates containing the 
appropriate antibiotics. These plates were 
grown overnight at 37°C and then colonies 
were transferred to 5mL of 2XYT medium 
with antibiotics. These cultures were grown 
overnight in the 37°C shaker at 225rpm. 
Next, 2mL from each sample was used to 
inoculate 200mL of 2XYT media. These 
larger cultures were grown in the 37°C 
shaker at 225rpm for 3 hours. After growth, 
the OD was checked and the cultures were 
induced with 100μL of IPTG.  
The samples were then placed in the 20°C 
shaker at 225rpm for 20 hours. The cells 
were harvested by centrifugation at 7000rpm 
for 7 minutes. The supernatants were 
decanted and the pellets were stored at          
-80°C.  
     The pellets were resuspended in lysis 
buffer and sonicated for 4 minutes with a 30 
second pulse time followed by 1 minute of 
wait time. After the cells were lysed, the 
samples were centrifuged for 1 hour at 
17000rpm. The pH of the supernatant was 
then tested and corrected to be 8.0 by the 
addition of 8M NaOH. Each supernatant 
was run through an affinity chromatography 
column with 100μL of Ni-NTA resin at the 
base. The supernatant flowed through the 
column slowly, so it was only passed 
through the column once. The column was 
washed with Tris-HCl wash buffer to 
remove any unbound proteins. The columns 
were then eluted 5 times with 100μL elution 
volumes. Samples were taken throughout 
this process (supernatant, pellet, flow-
through, washed resin, elution 2-3, and end 
resin) and mixed with 20μL of SDS dye to 
run on an SDS-PAGE gel.  
 
Large-Scale Protein Preparation 
For the large-scale prep, the BL21 10-4 
strain was used because it was shown to 
have the greatest expression of MBP-hCAR. 
A small sample was taken from the glycerol 
stock and plated on an agar plate with 
kanamycin. The plate was kept overnight at 
37°C for colony growth. Two isolated 
colonies were transferred to 2 test tubes 
containing 5mL of 2XYT liquid medium 
and kanamycin. The liquid cultures were 
placed in the 37°C shaker at 225rpm 
overnight. After one night of growth, the 
two test tubes were combined into a flask 
containing 1L of 2XYT medium and 
kanamycin. This culture was grown to an 
OD of 0.7 after which it was induced with 
500μL of IPTG and placed in the 20°C 
shaker at 225rpm for 20 hours. The cells 
were then harvested by centrifugation at 
7000rpm for 7 min and the pellets were 
stored at -80°C.  
     For the protein isolation, the pellet was 
first resuspended in 15mL of Tris-HCl lysis 
buffer containing 1.5μL of DNAse, 30μL 
PMSF, and 5μL of βME. The resulting 
solution was passed through the French 
Press one time at a pressure of 1500psi to 
lyse the cells. The lysate was then 
centrifuged for 1 hour at 17000rpm. The pH 
of the supernatant was measured at 7.97 and 
the supernatant was passed through an 
affinity chromatography column with a 
750μL bed volume of Ni-NTA resin at the 
bottom. The supernatant was allowed to pass 
through the column a total of two times to 
ensure that the desired protein had 
effectively bonded to the resin. The column 
was washed with 25mL of Tris-HCl wash 
buffer, and 5 elutions of 750μL each were 
taken. The concentration for each elution 
was measured using Bradford’s reagent 
(Table 3).  
 
Protein Purification and Concentration 
After MBP-hCAR was isolated via affinity 
chromatography, it was further purified by 
size-exclusion chromatography (SEC). A 
total of 2mL of protein from elutions 1, 2, 
and 3 from the Ni-NTA column were loaded 
onto a gel filtration machine equipped with 
an S200 SEC column. The column was 
equilibrated with gel filtration buffer 
containing: 20mM Tris-HCl, 100mM NaCl, 
.1mM EDTA, and 1mM DTT. The machine 
was programmed to collect 1.5mL fractions 
at a flow rate of 1mL/minute until the entire 
sample had been run through the column. To 
determine which peak corresponded with the 
desired protein, a sample from both the peak 
marked 69.19 (fraction 18) and that marked 
79.03 (fraction 26) were taken and run on 
SDS-PAGE. The resulting gel showed that 
peak 79.03 contained MBP-hCAR and that 
it had been successfully purified by the size-
exclusion chromatography (Figures 4 and 
5). The fractions corresponding to this peak 
were collected and the sample was 
concentrated down to 10mg/mL using an 
Amicon concentrating unit with a filter with 
a size cut-off of 10kDa. The concentrated 
sample was flash-frozen using liquid 
nitrogen to ensure that the protein was not 
damaged during the freezing process, and 
the frozen protein was stored at -80°C. 
 
Crystallization Screening 
To examine the structure of MBP-hCAR, 
two Peg-Ion crystallization screens were 
prepared. The first was MBP-hCAR alone, 
and the second was MBP-hCAR with 
CINPA-1. For the second screen, 80μL of 
MBP-hCAR was mixed with 2μL of 
CINPA-1. A robot was used to nanodispense 
small amounts of the protein sample into a 
3-well plate containing different amounts of 
each of the 96 Peg-Ion crystallization 
buffers. The screens were sealed and 
incubated at 25°C.  
 
Results 
Plasmids isolated from samples PCR5-5 and 
PCR10-1 showed 100% sequence identity to 
the MBP-hCAR sequence, but PCR10-2 














Table 1. The Results of Plasmid Preparation for 
pET15bMBP-hCAR.  
Five samples from the original PCR5 reaction and 
two samples from PCR10 were chosen to isolate 
plasmids. Of these plasmid preparations, samples 
PCR5-5, PCR10-1, and PCR10-2 showed high 
concentrations and were selected for sequence 
analysis. Of these three samples, PCR5-5 and 
PCR10-2 matched the theoretical sequence with 
100% identity. PCR10-2 failed to sequence. PCR5-1 
through PCR5-4 did not show strong enough 
isolation and were not sequenced.  
 
Although there were issues with the 
antibody binding to the Western blot 
(Figure 2), the band pattern of the stain 
shows that each culture produced MBP-
hCAR. The results were compared with each 
other and those that were thought to have the 
best expression of MBP-hCAR were 
selected for further experimentation. The 
selections were made so that both 




Figure 2. Western Blot Expression Screening. 
The left screen is for BL21 10 and RIPL 10 and the 
right screen is for BL21 5 and RIPL 5. The row of 
bands indicated by the black arrows represents MBP-
hCAR at approximately 75kDa. Each sample 
produced the desired protein, so their respective 
bands were compared against each other to determine 
which appeared to be expressed more strongly. Those 
selected are RIPL 10-3 (1), BL21 10-4 (2), RIPL 5-4 
(3), and BL21 5-2 (4).  
 
The BL21 strains showed faster growth rates 
than the RIPL strains. Both BL21 samples 
reached higher optical densities than RIPL 










Table 2. Sample ODs for Small-Scale Preparation. 
The optical density for each of the four observed-
growth colonies is shown above. Despite being 
grown for the same time, the BL21 cultures grew to a 
much higher OD than RIPL. 
4 
The SDS samples taken for the small-scale 
protein preparations were run on an SDS-
PAGE gel and the expression between each 
strain was compared against each other to 
determine that BL21 10-4, which showed 
the greatest concentration of MBP-hCAR, 
would be used for a larger prep (Figure 3).  
 






















Figure 3. SDS PAGE Results for Small-Scale 
Protein Preparation. 
The gel on top has samples BL21 5-2 and RIPL 5-4. 
In lane 6 and 7 are elution 2 and 3 from BL21 5-2, 
and in land 13 and 14 are elution 2 and 3 from RIPL 
5-4, respectively. Lane 5 contains the ladder, and the 
arrow designates the marker for 75kDa, which 
corresponds to the location of MBP-hCAR. The 
bottom gel has samples from BL21 10-4 and RIPL 
10-3. Lanes 5 and 7 contain BL21 10-4 elution 2 and 
3 respectively, and lanes 13 and 14 contain elution 2 
and 3 from RIPL 10-3. The large band circled in lane 
5 shows the highest concentration of MBP-hCAR and 
thus was chosen for further experimentation.  
 
Table 3 shows the total amount of MBP-
hCAR produced by the BL21 10-4 strain. 
The high concentrations of elutions 2 and 3 
show that this strain is highly effective for 
large-scale expression of MBP-hCAR. With 
more than 20mg of protein produced, this 
strain demonstrated the ability to produce 








Table 3. The Concentrations and Total Amount of 
Protein Isolated After Affinity Chromatography. 
The concentration was calculated using Bradford’s 
reagent. 2μL of protein was added to a mixture of 
200μL of Bradford’s reagent and 798μL of deionized 
water, and the absorbance at 595nm was measured 
using a UV spectrometer. The absorbance was 
multiplied by a factor of 10 to yield the concentration 
in mg/mL. The total protein was then calculated by 
multiplying the concentration by the volume of each 
elution (750μL). 
 
The size-exclusion chromatography machine 
produced the following chromatogram 
(Figure 4). The peak marked 79.03 is MBP-
hCAR.  The blue line measures absorbance 
at 260nm, and the sharpness of this peak 















Figure 4. The Chromatogram Produced by Size-
Exclusion Chromatography. 
The peak marked 79.03 is MBP-hCAR. This peak 
was distributed over 5 fractions, which were later 
combined into one vessel. The peaks marked 48.08 
and 69.19 were indicative of proteins larger than the 
~70kDa MBP-hCAR. The blue line measures the 
absorbance of the sample at 280nm, the wavelength 
used to show absorption by protein.  
The final SDS-PAGE (Figure 5) was run 
after SEC and Ni-NTA. Peak 2 contains 
isolated and purified MBP-hCAR, after 
SEC. MBP-hCAR is also seen in high 
concentration in lane 6, after Ni-NTA, but 
the sample is less pure.  










Figure 5. SDS-PAGE After Ni-NTA and SEC. 
Lane 1 contains the ladder. Lane 2 contains fraction 
26 from peak 79.03. Lane 3 contains fraction 18 from 
peak 69.19. The remaining lanes contain samples 
from the affinity chromatography column. Lane 2 
shows that peak 79.03 corresponds to MBP-hCAR. It 
also shows that MBP-hCAR has been successfully 
purified by size-exclusion chromatography. 
Comparing lanes 2 and 6 show that, although the 
protein is now more dilute, the majority of impurities 
have been removed from the sample.  
 
There are no results for the final 





This experiment successfully isolated and 
purified MBP-hCAR, a construct that 
contains the human nuclear receptor CAR as 
well as the Maltose Binding Protein (MBP) 
of E. coli.  MBP was chosen because it 
contains a genetic marker consisting of 6 
consecutive histidine residues. This tag has 
the benefit of allowing the protein to bind to 
the Ni-NTA resin of the affinity column for 
easier isolation8.  
     Beginning with the plasmid preparation, 
two separate PCR reactions were carried out 
to test the effect of template DNA 
concentration on amplification. Both 
reactions used Phusion DNA polymerase, 
which has an error rate more than 50-times 
lower than the standard Taq polymerase 
used in PCR reactions9, and both reactions 
successfully amplified the target DNA 
sequence. These reactions were then 
digested using Dpn1, a restriction enzyme 
that cleaves between the adenine and 
thymine residues of a methylated GATC 
inverted repeat10. Cleavage by this enzyme 
results in blunt ends in the recognition 
sequence of both the target plasmid as well 
as the PCR product, which must then be 
ligated together in order to form a complete 
plasmid containing the gene targeted for 
expression. When used to transform DH5α 
cells, the reaction mixture that contained 
5ng of template DNA was taken up more 
successfully by the cells. After overnight 
growth on agar plates, the plate inoculated 
with DH5α-5 had far more transformant 
colonies than that inoculated by DH5α-10 
cells. Because of this, 5 colonies were 
selected from DH5α-5 and 2 colonies were 
selected from DH5α-10. After the plasmids 
were isolated and sequenced, however, it 
was shown that both PCR5 and PCR10 
resulted in one successfully replicated 
plasmid, respectively. 
     During the expression-screening step of 
the experiment, 20 small cultures (5 from 
BL21 5, 5 from BL21 10, 5 from RIPL 5, 
and 5 from RIPL 10) were made. Both BL21 
and RIPL E. coli strains are competent, 
meaning that they are able to take up DNA 
from their surrounding environment. RIPL is 
a substrain of BL21 that is designed to 
contain extra tRNA genes and thus 
additional tRNAs11, which can be helpful in 
making protein translation more efficient. 
However, for this experiment, the BL21 
strain showed the greatest expression. These 
cultures were tested for expression of MBP-
hCAR by Western blot (Figure 2), an assay 
that utilizes antibodies that are specific to a 
certain antigen to determine whether that 
specific antigen is present12. After the 
addition of antibody specific to the desired 
protein, there appeared to be no interaction 
between the antibody and protein. This 
typically signifies that the target protein is 
not present. Testing the antibody with a 
protein known to be isolated, however, also 
resulted in the same non-interaction. Thus, it 
was reasoned that the error in the Western 
blot was due to the antibody, and that the 
identified band was indeed MBP-hCAR.  
     During the small-scale protein 
preparation, the 4 strains showing the 
highest expression in the Western blot were 
used to inoculate 4 small liquid cultures. 
2XYT was used as the growth medium of 
choice because it is enriched to allow faster 
growth and allowed the cells to be grown for 
longer durations13. For the observed growth 
cultures, the optimal OD range is said to be 
between 0.4-0.814. Once the culture’s OD is 
within this range it should be induced with 
IPTG, which is a molecularly engineered 
metabolite used to induce E. coli’s Lac 
operon. Unlike lactose, the natural inducer 
of the Lac operon, IPTG is not broken down 
by the organism15. This is beneficial for 
induction purposes because it allows 
continuous activation without loss of the 
inducing agent, such that the operon will be 
turned on longer and more efficiently. For 
both of the BL21 samples the ODs 
surpassed the ideal range before they were 
induced. This overgrowth may have led to 
competition for resources and premature cell 
death, causing the induction to be less 
successful. Based on the results of the 
protein preparation, though, it appears that 
the sample with the highest expression of 
MBP-hCAR, BL21 10-4, was also grown to 
the highest OD (Table 2). Furthermore, 
when running the samples through the Ni-
NTA affinity chromatography columns, the 
flow rate was slow in all samples except 
RIPL 5-4. For sample BL21 5-2, the column 
stopped flowing completely and the sample 
was quickly run through another clean 
column. Columns BL21 10-4 and RIPL 10-3 
were dried out to accelerate the flow. 
Though these techniques could have skewed 
the data regarding which strain had the best 
expression, BL21 10-4 showed much greater 
expression despite expedited flow through.  
     For the large-scale protein preparation, 
BL21 10-4 was chosen because it has been 
shown to produce high quantities of MBP-
hCAR under the desired growth conditions. 
A French Press was chosen to lyse the cells 
for two reasons: it allows the reaction 
volume to be much less than it would have 
been with sonication, and it provides a more 
complete and efficient lysis of cells16. 
Typically, the resuspended cells are passed 
through the French Press either 1 or 2 times. 
A single passage is enough to lyse 
approximately 75-percent of the cells, with a 
second passage lysing the remaining cells16. 
Because the lysate appeared to be 
thoroughly lysed after 1 passage through the 
French Press, it was decided that it would 
not be re-lysed to limit any potential damage 
caused by overexposing the protein to the 
high pressure produced by the French Press. 
After centrifuging the lysate, the supernatant 
was run through a Ni-NTA affinity 
chromatography column a total of 2 times. 
This ensured that MBP-hCAR, whose 
histidine tag is able to bind the resin, had 
ample opportunity to bind. A downside to 
this method is the possibility that proteins 
other than that with the histidine tag can 
bind the resin as well17. This means that, 
although the desired protein will be much 
more isolated than before, it might still have 
some impurities. 
     To remove these impurities, the eluted 
protein was passed through a size-exclusion 
chromatography column. This technique 
separates proteins based on size, with large 
proteins passing through more quickly than 
small proteins18. The S200 column chosen 
had a size limit of 200kDa. Since MBP-
hCAR is 70kDa, it would elute off the 
column toward the middle of the collection 
period and would not elute off the column 
prior to or after the collection period and be 
lost. Size-exclusion chromatography allows 
for more specific separation of proteins, and 
thus is another method by which purified 
MBP-hCAR was isolated. Although there is 
still slight contamination by other proteins 
after SEC (Figure 5), it was not enough to 
classify the protein as impure. Since SEC 
elutes the protein over a few separate 
fractions, it is possible for fractions to 
overlap such that similarly sized proteins are 
being eluted at the same time. This 
phenomenon gives rise to the low level of 
contamination, though it could be 
ameliorated by being more selective in 
determining which SEC fractions to collect, 
and thus collecting fewer total fractions. 
After collection, the protein was 
concentrated down to 10mg/mL using an 
Amicon concentrating unit with a filter size 
cutoff of 10kDa. This unit uses pressurized 
nitrogen gas to slowly force the buffer 
through the filter while the protein, which is 
too large to pass through the filter, remains 
behind. This allows the protein to reach a 
concentration suitable for further 
experimentation. After concentration, the 
protein was flash-frozen using liquid 
nitrogen. This prevented the ice shards that 
form during the normal freezing process 
from damaging the protein. Storage of the 
protein at -80°C allowed it to be kept long-
term for further experimentation. 
     Due to equipment malfunction, the 
crystallization screening experiment did not 
succeed. The robot did not properly dispense 
the Peg-Ion buffers into the appropriate 
wells, and the protein dispenser periodically 
became clogged. This resulted in 
inappropriate mixing between protein and 
buffer. Because of this, the protein was not 
able to crystallize, and no information 
regarding the mechanism of inactivation can 
be discerned regarding MBP-hCAR’s 




     Overall, this experiment was successful 
in isolating and purifying MBP-hCAR. It 
was shown that both BL21 and RIPL strains 
of E. coli could be manipulated to express 
MBP-hCAR at high levels, though BL21 
showed greater expression. Initial protein 
isolation was effectively performed using a 
Ni-NTA affinity chromatography column, 
and size-exclusion chromatography was 
successfully utilized to purify the remaining 
protein. Despite initial successes, this 
experiment was not effective in determining 
the structure of MBP-hCAR and its 





After isolation of MBP-hCAR, additional 
studies must be performed to better 
understand the structure and function of 
CAR. The primary focus of any additional 
experimentation should be to complete the 
attempted crystallization condition screens 
to show the structure of MBP-hCAR as well 
as structural changes when bound to a ligand 
such as CINPA-1. From there, treating 
MBP-hCAR with TEV protease will cleave 
off the Maltose-Binding Protein, allowing 
for sole isolation of CAR for further studies. 
Setting up crystal screens with CAR as well 
as with its associated ligands will help shed 
light on the binding mechanism of CAR’s 
LBD as well as demonstrate methods of 
ligand-mediated activation or inactivation of 
CAR, the latter of which can be used 
therapeutically to decrease multi-drug 
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